The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Sanofi (Inst); Sirius Medical (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; Lunaphore Technologies; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Paul D. Nathan
Consulting or Advisory Role - 4SC; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck; MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Paul Nghiem
Leadership - Society for Investigative Dermatology (SID)
Honoraria - UpToDate; UpToDate
Consulting or Advisory Role - 4SC; EMD Serono; Merck Sharp & Dohme; Pfizer; Pfizer/EMD Serono; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb; EMD Serono
Patents, Royalties, Other Intellectual Property - Patent filed: "Merkel cell polyomavirus T antigen-specific TCRs and uses thereof" (Inst); Patent pending for high affinity T cell receptors that target the Merkel polyomavirus.
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Sanofi/Regeneron
 
Philip Reimann
Employment - 4SC
Stock and Other Ownership Interests - 4SC; Adaptimmune; BioNTech; Bluebird Bio; Bristol-Myers Squibb; crispr therapeutics; Editas Medicine; Evotec; Medigene; Sartorius
 
Frank Hermann
Employment - 4SC
Leadership - 4SC
Patents, Royalties, Other Intellectual Property - I am partly holder of patent rights within 4SC AG.
 
Jürgen C. Becker
Consulting or Advisory Role - Amgen; eTheRNA; InProTher; Merck Serono; Sanofi/Regeneron
Speakers' Bureau - Amgen; Merck Serono; Novartis; Sanofi/Regeneron
Research Funding - Alcedis (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); IQvia (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - 4SC; Merck Serono